

Title (en)

PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES

Title (de)

PEPTIDINHIBITOREN DES INTERLEUKIN-23-REZEPTORS UND DEREN VERWENDUNG ZUR BEHANDLUNG ENTZÜNDLICHER ERKRANKUNGEN

Title (fr)

PEPTIDES INHIBITEURS DU RÉCEPTEUR DE L'INTERLEUKINE-23 ET LEUR UTILISATION POUR TRAITER DES MALADIES INFLAMMATOIRES

Publication

EP 3341011 A4 20190220 (EN)

Application

EP 16825301 A 20160715

Priority

- US 2015040658 W 20150715
- US 201514800627 A 20150715
- US 201562264820 P 20151208
- US 201662281123 P 20160120
- US 2016042680 W 20160715

Abstract (en)

[origin: WO2017011820A2] The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.

IPC 8 full level

A61K 38/20 (2006.01); **C07K 7/06** (2006.01); **C07K 7/08** (2006.01); **C07K 14/54** (2006.01)

CPC (source: EA EP KR)

A61K 9/50 (2013.01 - EA KR); **A61P 1/04** (2017.12 - EA EP); **A61P 1/16** (2017.12 - EA EP); **A61P 1/18** (2017.12 - EA EP); **A61P 3/00** (2017.12 - EA EP); **A61P 3/10** (2017.12 - EA EP); **A61P 7/00** (2017.12 - EA EP); **A61P 11/02** (2017.12 - EA EP); **A61P 11/06** (2017.12 - EA EP); **A61P 15/00** (2017.12 - EA EP); **A61P 17/06** (2017.12 - EA EP); **A61P 19/02** (2017.12 - EA EP); **A61P 29/00** (2017.12 - EA EP); **A61P 35/00** (2017.12 - EA EP); **A61P 37/02** (2017.12 - EA EP); **A61P 37/06** (2017.12 - EA EP KR); **C07K 7/06** (2013.01 - EA EP KR); **C07K 7/08** (2013.01 - EA EP KR); **A61K 38/00** (2013.01 - EA KR)

Citation (search report)

- [XP] WO 2016011208 A1 20160121 - PROTAGONIST THERAPEUTICS INC [US], et al
- [A] US 2013183755 A1 20130718 - GALLAGHER GRANT [US], et al
- See references of WO 2017011820A2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2017011820 A2 20170119; WO 2017011820 A3 20170223; AU 2016293619 A1 20180201; AU 2016293619 B2 20210225; BR 112018000691 A2 20180918; CA 2991984 A1 20170119; CL 2018000128 A1 20180615; CL 2018003322 A1 20190118; CL 2021000343 A1 20210806; CN 108348580 A 20180731; CN 108348580 B 20220510; CO 2018000349 A2 20180710; CR 201800029 A 20180605; DO P2018000010 A 20180330; EA 035733 B1 20200731; EA 035733 B9 20210114; EA 201890325 A1 20180629; EC SP18002929 A 20180331; EP 3341011 A2 20180704; EP 3341011 A4 20190220; HK 1257747 A1 20191025; HK 1259149 A1 20191129; IL 256827 A 20180329; JP 2018522008 A 20180809; JP 6858174 B2 20210414; KR 102513978 B1 20230327; KR 20180030663 A 20180323; MX 2018000542 A 20180627; NI 2018000008 A 20180629; PE 20180571 A1 20180404; PH 12018500086 A1 20180730; SG 10201912066S A 20200227; SV 2018005614 A 20180522; UA 123772 C2 20210602

DOCDB simple family (application)

US 2016042680 W 20160715; AU 2016293619 A 20160715; BR 112018000691 A 20160715; CA 2991984 A 20160715; CL 2018000128 A 20180115; CL 2018003322 A 20181122; CL 2021000343 A 20210209; CN 201680049562 A 20160715; CO 2018000349 A 20180115; CR 201800029 A 20160715; DO 2018000010 A 20180110; EA 201890325 A 20160715; EC PI201802929 A 20180115; EP 16825301 A 20160715; HK 19100122 A 20190104; HK 19101174 A 20190123; IL 25682718 A 20180110; JP 2018501178 A 20160715; KR 20187004612 A 20160715; MX 2018000542 A 20160715; NI 2018000008 A 20180111; PE 2018000053 A 20160715; PH 12018500086 A 20180109; SG 10201912066S A 20160715; SV 2018005614 A 20180115; UA A201801482 A 20160715